Nichi-Iko Sanofi-Aventis JV To Develop Biosimilars Within Five Years
This article was originally published in PharmAsia News
Nichi-Iko president Yuichi Tamura said the company plans to develop and commercialize biosimilar products in Japan within five years through a joint venture with Sanofi-Aventis
You may also be interested in...
SINGAPORE - European drug maker Sanofi-Aventis is scouting for Asia-centric joint ventures or collaborative arrangements to accelerate its presence in the biosimilars space. Sanofi is hoping to make up ground as some of its global peers have advanced in the segment to capitalize on some of the biggest revenue drivers expected to unfold in the next five to eight years
Potentially transformative treatments for severe asthma, COPD and osteoarthritis are among some of the below-the-radar projects the Swiss major is advancing, according to Vas Narasimhan.
Pharma’s latest partnerships focus on Duchenne muscular dystrophy with Precision Biosciences, protein degradation with Seed. Bristol and Schrodinger team in computational drug discovery.